IMA 203CD8
Alternative Names: IMA-203CD8; IMA-203CD8 GEN2Latest Information Update: 03 Jun 2024
At a glance
- Originator Immatics US
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 14 May 2024 Efficacy and adverse events data from the phase I ACTengine trial in Solid tumours released by Immatics
- 14 Nov 2023 Efficacy, pharmacokinetics and safety data from a phase I trial in Solid tumours released by Immatics
- 11 Aug 2022 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Recurrent) in Germany (Infusion) (NCT03686124)